Insider filing · TVTX
Christopher R. Cline
CHIEF FINANCIAL OFFICER
profile →
Travere Therapeutics, Inc.
TVTX · Healthcare · 74 filings in 24 months
ticker →
Christopher R. Cline sold $304K of Travere Therapeutics (TVTX)
Executed Apr 14, disclosed Apr 15, 1 day later.
Value, as filed
$304K
7,239 sh × $41.93
Executed
Apr 14
the trade date, as filed
Disclosed
Apr 15
1 day after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
CCChristopher R. Cline (CHIEF FINANCIAL OFFICER) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Travere Therapeutics, Inc. (TVTX). The largest single filing was $3.1M of TVTX (50,108 sh across 3 lots, as filed), executed Sep 15.
The name
TVTXHealthcare · Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Christopher R. Cline in TVTX
TVTXSALE
Travere Therapeutics, Inc.
$3.1M50,108 sh across 3 lots
Exec Sep 15
Filed Sep 17 · 9:30 PM ET TVTXSALE Travere Therapeutics, Inc. $102K
2,181 sh × $46.65
Exec May 5
Filed May 6 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $233K
7,242 sh × $32.12
Exec Feb 3
Filed Feb 3 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $700K
20,000 sh × $35.01
Exec Dec 1 2025
Filed Dec 3 2025 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $104K
5,192 sh × $20.12
Exec Feb 3 2025
Filed Feb 4 2025 · 5:30 PM ET